Literature DB >> 16086367

Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle.

David E Sosnovik1, Eyk A Schellenberger, Matthias Nahrendorf, Mikhail S Novikov, Takashi Matsui, George Dai, Fred Reynolds, Luanda Grazette, Anthony Rosenzweig, Ralph Weissleder, Lee Josephson.   

Abstract

The ability to image cardiomyocyte apoptosis in vivo with high-resolution MRI could facilitate the development of novel cardioprotective therapies. The sensitivity of the novel nanoparticle AnxCLIO-Cy5.5 for cardiomyocyte apoptosis was thus compared in vitro to that of annexin V-FITC and showed a high degree of colocalization. MRI was then performed, following transient coronary artery (LAD) occlusion, in five mice given AnxCLIO-Cy5.5 and in four mice given an identical dose (2 mg Fe/kg) of CLIO-Cy5.5. MR signal intensity and myocardial T2* were evaluated, in vivo, in hypokinetic regions of myocardium in the LAD distribution. Ex vivo fluorescence imaging was performed to confirm the in vivo findings. Myocardial T2* was significantly lower in the mice given AnxCLIO-Cy5.5 (8.1 versus 13.2 ms, P<0.01), and fluorescence target to background ratio was significantly higher (2.1 versus 1.1, P<0.01). This study thus demonstrates the feasibility of obtaining high-resolution MR images of cardiomyocyte apoptosis in vivo with the novel nanoparticle, AnxCLIO-Cy5.5. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086367     DOI: 10.1002/mrm.20617

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  83 in total

1.  Small-animal molecular imaging methods.

Authors:  Robert A de Kemp; Frederick H Epstein; Ciprian Catana; Benjamin M W Tsui; Erik L Ritman
Journal:  J Nucl Med       Date:  2010-05-01       Impact factor: 10.057

Review 2.  Targeted probes for cardiovascular MRI.

Authors:  Ritika Uppal; Peter Caravan
Journal:  Future Med Chem       Date:  2010-03       Impact factor: 3.808

Review 3.  Approaching the asymptote: obstacles and opportunities for nanomedicine in cardiovascular disease.

Authors:  Sascha N Goonewardena
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

Review 4.  CMR for characterization of the myocardium in acute coronary syndromes.

Authors:  Erica Dall'Armellina; Theodoros D Karamitsos; Stefan Neubauer; Robin P Choudhury
Journal:  Nat Rev Cardiol       Date:  2010-09-21       Impact factor: 32.419

5.  Molecular MRI of acute necrosis with a novel DNA-binding gadolinium chelate: kinetics of cell death and clearance in infarcted myocardium.

Authors:  Shuning Huang; Howard H Chen; Hushan Yuan; Guangping Dai; Daniel T Schuhle; Choukri Mekkaoui; Soeun Ngoy; Ronglih Liao; Peter Caravan; Lee Josephson; David E Sosnovik
Journal:  Circ Cardiovasc Imaging       Date:  2011-08-11       Impact factor: 7.792

6.  Nanodiscs as a Modular Platform for Multimodal MR-Optical Imaging.

Authors:  Christiane E Carney; Ivan L Lenov; Catherine J Baker; Keith W MacRenaris; Amanda L Eckermann; Stephen G Sligar; Thomas J Meade
Journal:  Bioconjug Chem       Date:  2015-04-09       Impact factor: 4.774

Review 7.  [Advances in cardiovascular medicine through molecular imaging].

Authors:  M Nahrendorf; R Weissleder
Journal:  Radiologe       Date:  2007-01       Impact factor: 0.635

8.  Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents.

Authors:  Peter Caravan; Christian T Farrar; Luca Frullano; Ritika Uppal
Journal:  Contrast Media Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 3.161

9.  Molecular MRI of Atherosclerotic Plaque With Targeted Contrast Agents.

Authors:  David E Sosnovik; Peter Caravan
Journal:  Curr Cardiovasc Imaging Rep       Date:  2009-04-01

Review 10.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.